David L. Murray
Mayo Clinic
Internal medicinePathologyMolecular biologyAntibodyMass spectrometryMonoclonalChemistryMyeloma proteinImmunologyMultiple myelomaSerum protein electrophoresisImmunofixationAL amyloidosisAmyloidosisIn patientImmunoglobulin light chainChromatographyMonoclonal antibodyMedicineBiologyGastroenterology
140Publications
26H-index
2,630Citations
Publications 142
Newest
#1Erica M. Fatica (Mayo Clinic)
#2Mark A Martinez (Mayo Clinic)H-Index: 1
Last. Angela Dispenzieri (Mayo Clinic)H-Index: 138
view all 12 authors...
Abstract null null Background null Plasma cell disorders (PCDs) are typically characterized by excessive production of a single immunoglobulin, defined as a monoclonal protein (M−protein). Some patients have more than one identifiable M−protein, termed biclonal. Traditional immunofixation electrophoresis (IFE) cannot distinguish if two bands of the same isotype represent biclonal proteins or M−proteins with some other feature. A novel assay using immunoenrichment coupled to matrix-assisted laser...
Source
#1David F. Keren (UM: University of Michigan)H-Index: 22
#2Gregary Bocsi (CU: University of Colorado Boulder)
Last. David L. MurrayH-Index: 26
view all 15 authors...
CONTEXT.— The process for identifying patients with monoclonal gammopathies is complex. Initial detection of a monoclonal immunoglobulin protein (M protein) in the serum or urine often requires compilation of analytical data from several areas of the laboratory. The detection of M proteins depends on adequacy of the sample provided, available clinical information, and the laboratory tests used. OBJECTIVE.— To develop an evidence-based guideline for the initial laboratory detection of M proteins....
Source
#1Anan A. Abu Rmilah (Mayo Clinic)H-Index: 2
#2Robert Fencl (Mayo Clinic)
Last. Michael D. Leise (Mayo Clinic)H-Index: 21
view all 8 authors...
OBJECTIVE The role of MZ phenotype of α 1 antitrypsin (α1AT) deficiency as a potential cofactor in advanced liver disease arising from other primary etiologies is not widely understood. In the general population, MZ phenotype accounts for 2-4% in Europe and 2-7.1% in North America. The aim of this study was to determine the prevalence of the MZ phenotype among various etiologies of cirrhosis in the U.S. in the modern era and its impact on pulmonary function before and after liver transplantation...
Source
#1Patrick W. Mellors (Mayo Clinic)H-Index: 3
#2Mindy Kohlhagen (Mayo Clinic)H-Index: 7
Last. Angela Dispenzieri (Mayo Clinic)H-Index: 138
view all 9 authors...
Source
#1Patrick W. Mellors (Mayo Clinic)H-Index: 3
#2Surendra DasariH-Index: 40
Last. Maria Alice V. Willrich (Mayo Clinic)H-Index: 21
view all 27 authors...
Source
#1Eli Muchtar (Mayo Clinic)H-Index: 21
#2Angela Dispenzieri (Mayo Clinic)H-Index: 138
Last. Taimur Sher (Mayo Clinic)H-Index: 21
view all 38 authors...
Immunoglobulin light chain (AL) amyloidosis is a clonal plasma cell disorder leading to progressive and life-threatening organ failure. The heart and the kidneys are the most commonly involved organs, but almost any organ can be involved. Because of the nonspecific presentation, diagnosis delay is common, and many patients are diagnosed with advanced organ failure. In the era of effective therapies and improved outcomes for patients with AL amyloidosis, the importance of early recognition is fur...
Source
Source
#1Surbhi Sidana (Stanford University)H-Index: 14
#2Surendra DasariH-Index: 40
Last. Morie A. GertzH-Index: 136
view all 10 authors...
Patients with immunoglobulin M (IgM) light chain (AL) amyloidosis have a distinct clinical presentation compared with those with non-IgM amyloidosis. We hypothesized that differential immunoglobulin light-chain variable region (IGVL) gene usage may explain the differences in organ involvement, because IGVL usage correlates with organ tropism. IGVL usage was evaluated by mass spectrometry of amyloid deposits (IgM, n = 45; non-IgM, n = 391) and differed across the 2 groups. In the λ family, LV2-08...
Source
#1David L. Murray (Mayo Clinic)H-Index: 26
#2Surendra Dasari (Mayo Clinic)H-Index: 40
The diagnosis of myeloma and other plasma cell disorders has traditionally been done with the aid of electrophoretic methods, whereas amyloidosis has been characterized by immunohistochemistry. Mass spectrometry has recently been established as an alternative to these traditional methods and has been proved to bring added benefit for patient care. These newer mass spectrometry-based methods highlight some of the key advantages of modern proteomic methods and how they can be applied to the routin...
Source
#1Jithma P. Abeykoon (Mayo Clinic)H-Index: 11
#2David L. Murray (Mayo Clinic)H-Index: 26
Last. Prashant Kapoor (Mayo Clinic)H-Index: 39
view all 23 authors...
Measurable residual disease (MRD) assessment by marrow-based next-generation flow cytometry (NGF) following autologous stem cell transplantation (ASCT) may lead to false-negative results due to patchy marrow involvement and extramedullary disease in patients with multiple myeloma. We assessed the value of simultaneous MRD evaluation with NGF and serum matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MASS-FIX). Of all 61 complete responders who were NGF-negative for M...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.